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Lindsay R Young1, Susan K Raatz1,4*, William Thomas2, J Bruce Redmon3 and Mindy S Kurzer1Abstract
Background: Total fat and omega-3 fatty acids in the diet may affect breast cancer risk by altering estrogen
metabolism. The purpose of this study was to elucidate the effects of differing total fat and omega-3 fatty acid
content of diets on a panel of urinary estrogens and metabolites.
Findings: A controlled, cross-over feeding trial was conducted in postmenopausal women using three test diets:
high fat diet (HF; 40% energy from fat), low fat diet (LF; 20% of energy from fat) and low fat, high omega-3 diet
(LFn3; 23% energy from fat; 3% omega-3 fatty acids) for 8 week periods. Urinary hormone concentrations for 16
women were compared among diets using a linear mixed model, and within diet comparisons were made using
paired t-tests. Urinary excretion of estrone was greater after the LF and LFn3 compared to the HF (P = 0.004).
Estrone excretion was increased from baseline within the LF only (P = 0.02). Total estrone + estradiol + estriol
increased from baseline with LF (P = 0.02) and was greater than the other two diets at 8 weeks (P = 0.03). There
were no effects on estrogen metabolites, including the 2-hydroxy estrone:16α-hydroxy estrone ratio.
Conclusions: The results of this study indicate that urinary sex hormone metabolism was modestly altered in
postmenopausal women by a low fat dietary intervention.
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Introduction
High concentrations of estrogens in blood and urine are
associated with increased risk of breast cancer in post-
menopausal women [1], and one hypothesis is that this
increased risk is mediated by sex hormone metabolism.
Low fat diets resulted in significant reductions in cir-
culating estrogens in some studies in postmenopausal
women [2-4]. Dietary omega-3 fatty acids (n-3) may sup-
press tumorigenesis by inhibition of inflammatory eico-
sanoids, suppression of aromatase, and conversion of
androgens to estrogens [5].
In addition to promoting growth via interaction with
estrogen receptors, circulating estrogens are metabolized* Correspondence: susan.raatz@ars.usda.gov
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reproduction in any medium, provided the orby hydroxylation reactions resulting in an array of me-
tabolites with varying biological activity relative to the
parent estrogens, with some having genotoxic activity
[6]. Sixteen-α-hydroxy estrone (16αOH-E1) is a potent
mitogen, tumor initiator, and tumor promoter in vitro
[7]. 16α-hydroxylation of estrogens was enhanced in
women with breast cancer relative to healthy controls
[8,9]. A higher ratio of 2-hydroxy estrone (2OH-E1) to
16αOH-E1 (2:16αOH-E1 ratio) indicated decreased
breast cancer risk in some studies [10,11]; however,
other investigations do not support this association
[12,13].
We have previously shown that a high fat diet elevates
plasma estradiol [14]. The purpose of the present stu-
dy was to determine the effects of diets with varying
amounts of fat and n-3 on urinary estrogens and estro-
gen metabolites in healthy postmenopausal women. We
hypothesized that compared to a high fat diet, diets low
in fat or low in fat with high n-3 would decreaseLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cinogenic 4-hydroxy metabolites.Excluded (n=113)
Not meeting inclusion criteria (n=68)
Declined to participate (n=45)
Excluded (n = 2)
Elevated FSH (n=1)
Inadequate urine collection (n=1)
Biological samples analysed (n = 18)
(n=18 HF, 17 LF, 17 LFn3)
Randomized (n=24)
Excluded (n=6)
Not completing 2 diet treatments (n=6)
Statistical analysis (n = 16)
(n=15 HF, 15LF, 16 LFn3)
Figure 1 Flow diagram of participants from screening to
data analysis.Subjects and methods
Experimental protocol
Complete details of the study design and treatments are
described elsewhere [14]. The effects of controlled test
diets: a high fat diet (HF; 40% energy as fat, 15% energy
as protein, and 45% energy as carbohydrate), a low fat
diet (LF; 20% energy as fat, 15% energy as protein, and
65% energy as carbohydrate) and a low fat diet with n-3
fatty acids (LFn3; 23% energy as fat [3% n-3], 15% energy
as protein, and 62% energy as carbohydrate) on urinary
estrogen metabolism were compared in a randomized,
cross-over trial. All nutrient analysis was performed by a
registered dietitian (SKR) using the Nutritionist V nutri-
ent analysis program (Axxya Systems, Stafford, TX).
Subjects consumed each diet in random order for 8
weeks with a 6–12 week washout between treatments.
Reported dietary compliance was >99% for energy and
>99.5% for omega-3 fatty acids [14].
The study was carried out from 2004–2008. The study
was approved by the U.S. Army Medical Research and
Materiel Command’s Human Subjects Research Review
Board and the University of Minnesota Committee for
the Use of Human Subjects in Research. Written in-
formed consent was obtained from all subjects. The trial
was retrospectively registered at www.clinicaltrials.gov as
NCT01824498.Table 1 Characteristics of study subjects at baselinea
Characteristic Value
Age (years) 58 ± 6
Body weight (kg) 74 ± 11
Height (cm) 165 ± 5
BMI (kg/m2) 27 ± 4
Systolic blood pressure (mmHg) 118 ± 15
Diastolic blood pressure (mmHg) 71 ± 8





aAll values are means ± standard deviations except ethnic groups, which are n (%);
n = 16.
bBaseline follicle stimulating hormone values for all women ≤ 55 years old; n = 11.Subjects
Subject characteristics and recruitment are discussed
elsewhere [14]. Participants were healthy postmeno-
pausal women; age 45 – 70 years; had a body mass index
of 19 – 32 kg/m2; had not lost or gained more than 5
pounds in the last 6 months; and had not used fish oil
supplements or hormone replacement therapy for 2
months prior to the trial. Subjects were excluded if they
had any active disease process, used prescription medi-
cations, or had both ovaries removed. None of the par-
ticipants had prior a prior breast cancer diagnosis.
Seventeen subjects completed all three dietary treat-
ments and one subject completed two treatments. One
subject was excluded from the analysis because her fol-
licle stimulating hormone concentration was intermit-
tently in the premenopausal range. Another subject was
excluded due to improperly collected urine specimens.
One subject was missing urine samples for HF. In total,
15 subjects completed HF, 15 subjects completed LF,
and 16 subjects completed LFn3 and are included in the
final analysis. Figure 1 illustrates the flow of participants
through the trial.Urine collection
Subjects collected two consecutive 24-hour urine spe-
cimens at home on weeks 0 and 8 of each treatment
period. Urine was pooled and sodium azide was added
to 0.1%. Aliquots were immediately stored at −20°C until
analysis.
Plasma phospholipid fatty acids
Plasma phospholipid fatty acids (PLFA) were analyzed
by gas chromatography (Lipid Technologies, Austin,
Table 2 Baseline, 8 weeks, and change from baseline to 8 weeks concentrations for n3 and n6 plasma phospholipid
fatty acids in μg/ml1
High fat Low fat Low fat + n-3
n = 17 n = 16 n = 17 p-value2
18:2n6
Baseline 280.69 ± 14.57 284.66 ± 14.76 293.95 ± 14.59 0.41
8 weeks 285.49 ± 12.54a 269.21 ± 12.86a 233.08 ± 12.59b* 0.0006
Δ 8 weeks 4.81 ± 10.90a −16.08 ± 11.29a −60.85 ± 10.95b 0.0001
p-value3 0.66 0.16 < 0.0001
18:3n3
Baseline 4.00 ± 0.86 4.51 ± 0.88 3.22 ± 0.86 0.34
8 weeks 2.57 ± 0.45a 3.12 ± 0.47a 6.85 ± 0.45b* < 0.0001
Δ 8 weeks −1.43 ± 0.79a −1.30 ± 0.82a 3.62 ± 0.79b < 0.0001
p-value3 0.08 0.12 < 0.0001
20:4n6
Baseline 120.62 ± 7.83 121.51 ± 7.94 126.04 ± 7.84 0.59
8 weeks 107.89 ± 7.14a* 135.62 ± 7.34b* 100.12 ± 7.17a* 0.0001
Δ 8 weeks −12.72 ± 5.13a 13.47 ± 5.33b −25.90 ± 5.16a < 0.0001
p-value3 0.02 0.02 < 0.0001
20:5n-3
Baseline 11.43 ± 1.77 11.80 ± 1.82 9.69 ± 1.78 0.49
8 weeks 6.89 ± 1.80a* 9.99 ± 1.87a 29.86 ± 1.81b* < 0.0001
Δ 8 weeks −4.54 ± 1.94a −1.91 ± 2.02a 20.17 ± 1.96b < 0.0001
p-value3 0.02 0.35 < 0.0001
22:5n-3
Baseline 9.94 ± 0.78 10.56 ± 0.79 10.72 ± 0.78 0.49
8 weeks 8.41 ± 0.88a* 11.04 ± 0.91b 13.45 ± 0.89c* < 0.0001
Δ 8 weeks −1.52 ± 0.69a 0.36 ± 0.72a 2.73 ± 0.70b < 0.0001
p-value3 0.03 0.62 0.0003
22:6n-3
Baseline 30.18 ± 2.82 28.90 ± 2.89 29.68 ± 2.83 0.89
8 weeks 24.06 ± 3.77a* 35.03 ± 3.90b* 55.00 ± 3.78c* < 0.0001
Δ 8 weeks −6.12 ± 2.56a 5.95 ± 2.65b 25.32 ± 2.57c < 0.0001
p-value3 0.02 0.03 < 0.0001
Total n-3
Baseline 59.71 ± 5.33 60.07 ± 5.42 56.75 ± 5.34 0.68
8 weeks 44.50 ± 6.37a* 62.86 ± 6.60b 110.10 ± 6.41c* < 0.0001
Δ 8 weeks −15.21 ± 4.95a 2.55 ± 5.14b 54.36 ± 4.98c < 0.0001
p-value3 0.004 0.62 < 0.0001
Total n-6
Baseline 452.87 ± 21.30 456.78 ± 21.57 468.55 ± 21.34 0.53
8 weeks 432.99 ± 18.17a 458.41 ± 18.74a 370.63 ± 18.25b* 0.0005
Δ 8 weeks −19.85 ± 14.82a −0.58 ±15.34a −97.85 ± 14.89b < 0.0001
p-value3 0.19 0.97 < 0.0001
1All values are LS means ± standard error.
2p-value for effect of treatment across the three diets evaluated using a general linear mixed model. Values with differing letters as a superscript are significantly different at p < 0.05.
3p-value for paired t-test comparing baseline and 8 weeks means within each diet.
*8 week mean is significantly different from baseline mean.
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Table 3 Baseline and 8 week values for urinary estrogens and metabolites for the HF, LF and LFn3a
Analyte HF LF LFn3 P-valued
n = 15b n = 15c n = 16
Estrone (E1) (nmol/day)
Baseline 6.7 (4.8, 9.5) 7.2 (5.1, 10.1) 8.1 (5.8, 11.5) 0.36
8 weeks 6.3 (4.4, 9.1) § 9.9 (6.9, 14.2) †** 8.5 (5.9, 12.1) † 0.004
P-valuee 0.39 0.02 0.92
Estradiol (E2) (nmol/day)
Baseline 2.0 (1.0, 3.8) 2.2 (1.2, 4.3) 1.4 (0.7, 2.6) 0.36
8 weeks 1.0 (0.5, 2.1) 2.1 (1.0, 4.4) 1.7 (0.8, 3.4) 0.12
P-valuee 0.37 0.47 0.83
Estriol (E3) (nmol/day)
Baseline 7.2 (3.1, 16.8) 8.5 (3.6, 19.9) 10.8 (4.7, 25.0) 0.62
8 weeks 11.8 (6.3, 22.0) 14.3 (7.7, 26.7) 11.7 (6.3, 21.5) 0.79
P-valuee 0.84 0.12 0.64
E1 + E2 + E3 (nmol/day)
Baseline 22.9 (15.3, 34.4) 24.8 (16.6, 37.1) 23.0 (15.4, 34.2) 0.77
8 weeks 21.5 (14.3, 32.2)§ 35.7 (23.9, 53.4)†** 26.8 (18.1, 39.8)§† 0.03
P-valuee 0.51 0.02 0.60
2-hydroxyestrone (2OH-E1) (nmol/day)
Baseline 22.7 (16.5, 31.2)§† 25.0 (18.2, 34.4)§ 18.5 (13.5, 25.3)† 0.02
8 weeksf 17.6 (13.7, 22.7) 20.4 (15.8, 26.3) 24.1 (18.8, 30.9) 0.23
P-valuee 0.19 0.81 0.29
2-methoxyestrone (2-ME1)(nmol/day)
Baseline 1.6 (0.7, 3.8) 3.4 (1.5, 7.8) 3.1 (1.4, 7.1) 0.21
8 weeks 1.4 (0.7, 3.1) 2.1 (0.9, 4.5) 3.3 (1.5, 7.1) 0.23
P-valuee 0.98 0.48 0.91
2-methoxyestradiol (2-ME2) (nmol/day)
Baseline 1.3 (0.6, 3.3) 3.9 (1.6, 9.4) 1.7 (0.7, 3.9) 0.09
8 weeks 0.9 (0.4, 2.1) 1.0 (0.4, 2.3) 1.7 (0.8, 4.0) 0.39
P-valuee 0.84 0.08 0.57
4-hydroxyestrone (4OH-E1) (nmol/day)
Baseline 0.78 (0.51, 1.21) 1.08 (0.70, 1.68) 1.17 (0.76, 1.80) 0.21
8 weeks 0.92 (0.66, 1.27) 1.05 (0.76, 1.45) 1.28 (0.93, 1.75) 0.25
P-valuee 0.64 0.93 0.50
16α-hydroxyestrone (16αOH-E1) (nmol/day)
Baseline 2.03 (1.10, 3.75) 2.39 (1.29, 4.44) 1.70 (0.93, 3.11) 0.62
8 weeks 1.50 (0.82, 2.74) 2.34 (1.27, 4.29) 2.03 (1.12, 3.65) 0.52
P-valuee 0.47 0.22 0.32
Total Estrogens (nmol/day)
Baseline 73.7 (52.7, 100.1) 83.7 (60.9, 115.0) 72.8 (53.1, 99.6) 0.38
8 weeks 65.5 (45.8, 93.8) 86.4 (60.7, 123.0) 80.6 (57.0, 113.9) 0.27
P-valuee 0.78 0.54 0.40
2:16αOH-E1 ratio (nmol/day)
Baseline 11.3 (5.4, 23.6) 10.5 (5.0, 21.9) 10.8 (5.3, 22.4) 0.98
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Table 3 Baseline and 8 week values for urinary estrogens and metabolites for the HF, LF and LFn3a (Continued)
8 weeks 11.9 (5.7, 25.2) 10.0 (4.7, 21.3) 10.4 (5.0, 21.7) 0.90
P-valuee 0.90 0.12 0.72
HF: high fat diet; LF: low fat diet; LFn3: low fat + omega-3 fatty acids diet; E1: estrone;
2:16αOH-E1 ratio: 2-hydroxy estrone:16α-hydroxy estrone ratio.
aAll values are geometric means (95% confidence interval).
bOne subject was missing urines for HF diet, thus n = 15 for HF.
cOne subject was missing urines for LF diet, thus n = 15 for LF.
dP-value for effect of treatment across the three diets; values with differing symbols (§,†) as a superscript are significantly different.
eP-value for paired t-test comparing baseline and 8 weeks means within each diet.
**8 weeks mean is significantly different from baseline mean.
f8 weeks means were adjusted for baseline 2OH-E1.
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determine the effects of dietary treatments on PLFA
content (μg/ml) of linoleic acid (LA, 18:2n6), α-linolenic
acid (ALA, 18:3n3), arachidonic acid (AA, 20:4n6), ei-
cosapentaenoic acid (EPA, 20:5n3) and docosahexaenoic
acid (DHA, 22:6n3), total n3, total n6 and the n3/n6
ratio.
Estrogen metabolite assay by LC/MS-MS
LC-MS methods were used to determine urinary estrogens
and estrogen metabolites [15,16]. Unless otherwise noted,
all laboratory chemicals were obtained from Fisher Scien-
tific (Pittsburg, PA). 10 μL of deuterated-estrogen metabo-
lite internal standard solution (ISS; C/D/N Isotopes, Inc.,
Pointe-Claire, Quebec, Canada) containing representative
analytes of each class of compounds were added to dupli-
cate 1.0 ml urine aliquots, followed by 1.0 mL of freshly
prepared enzymatic hydrolysis buffer containing 2 mg of
L-ascorbic acid, 5 μL of β-glucuronidase/sulfatase (Type
H-2; Sigma-Aldrich, St Louis, MO), and 1.0 mL of 0.15 M
sodium acetate buffer (pH 4.1) and incubated overnight at
37°C.
Samples were extracted with ethyl ether and evapo-
rated to dryness at 40°C under nitrogen. 25 μL of 0.1 M
sodium bicarbonate buffer with 0.1% ascorbic acid (pH
at 9.0) and 25 μL of dansyl chloride solution (3 mg/mL
in acetone; Lancaster Synthesis, Inc., Pelham, NH) were
added to each dried sample. Each sample was heated at
65°C for 6 minutes to form estrogen metabolite and deu-
terated estrogen metabolite dansyl derivatives. Calibra-
tion standards (Steraloids, Inc., Newport, RI) and quality
control samples were similarly hydrolyzed, extracted,
and derivatized.
Chromatographic separation was performed on a 100 ×
0.5 mm (i.d.) Zorbax SB-C18 column 1.8μm particle size
(Agilent Technologies, Santa Clara, CA). The mobile
phase consisted of two eluents, solvent A (50 mL/L aceto-
nitrile + 950 mL/L H2O containing 1 mL/L formic acid)
and solvent B (475 mL/L acetonitrile + 475 mL/L metha-
nol + 50 mL/L H2O containing 1 mL/L formic acid). LC/
MS-MS analysis was performed on a Thermo Electron
Quantum Discovery Max Triple Quadrupole Instrument.Quantitative analysis was performed using Thermo Elec-
tron Xcalibur proprietary software. All samples from a
given subject were batch analyzed. Intra-batch coefficients
of variation varied from 5.1 – 12.2%. Inter-batch coeffi-
cients of variation for quality control samples varied from
6.3 – 27.9% among hormones.
Statistical analysis
Data for urinary sex hormone metabolites were not nor-
mally distributed and are reported as geometric means
and 95% confidence intervals. SAS Proc Mixed (SAS ver-
sion 9.2, SAS Institute Inc., Cary, NC; 2002–2008) was
used to fit a mixed effects linear model for each out-
come with a random effect for subject to account for
multiple correlated measurements within each subject.
These effect models handled isolated missing values and
were used to assess period and carryover effects. Least
squares means generated from the mixed model were
compared between treatments. Paired t-tests were ap-
plied to within diet differences. A P-value of < 0.05 was
considered statistically significant.
Results
Study participants were slightly overweight (mean BMI
27 kg/m2, Table 1) mostly white (88%) middle-aged
women (mean age 58 ± 6 years).
Plasma phospholipid fatty acids
The results for n-3 and n-6 in PLFA are presented in
Table 2. The LFn3 diet, which was low fat with supple-
mental n-3 promoted enhanced inclusion of total n-3,
ALA, EPA and DHA into PLFA compared to the HF
and LF diets (all p < 0.0001). The increases in n-3 were
accompanied by a reduction in total n-6, LA, and ARA.
In comparison to HF, LF promoted increased ARA and
DHA (p=.02, p=.03, respectively).
Urinary sex hormones
Urinary estrone (E1) excretion was significantly greater
after LF and LFn3 compared to HF (P = 0.004, Table 3),
although E1 excretion was significantly increased from
baseline with LF only (P = 0.02). Excretion of the sum of
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greater with LF than HF at 8 weeks (P = 0.03) and E1+
E2 + E3 increased significantly from baseline to 8 weeks
with LF (P = 0.02). Urinary excretion of 2OH-E1, 2-
methoxy estrone (2-ME1), 2-methoxy estradiol (2-ME2),
4-hydroxy estrone (4OH-E1), 16αOH-E1, 2:16αOH-E1
ratio and total estrogens were not significantly different
among test diets at 8 weeks. Urinary 2-hydroxy estradiol
(2OH-E2), 4-hydroxy estradiol (4OH-E2), 4-methoxy es-
trone (4-ME1), and 4-methoxy estradiol (4-ME2) were
undetectable in urine.
Discussion
Estrone excretion was significantly greater with LF and
LFn3 compared to HF, although there was little overall
change in urinary hormone metabolites. The sum of all
estrogens and metabolites assayed in this study (Total
Estrogens) did not differ among diets at 8 weeks. We pre-
viously reported the effects of the test diets on plasma sex
hormones [14]. In blood, E2 concentration increased sig-
nificantly with HF (P = 0.03) and decreased slightly, but
non-significantly with LF (P = 0.10) [14]. Therefore, we
anticipated changes in sex hormone metabolism measured
in urine. We saw no change in urinary sex hormone me-
tabolite excretion even though changes in the parent hor-
mones E1 and E2 were observed. Limiting factors include
the high variability (wide confidence intervals) of urinary
hormones and our small sample size.
We anticipated that LF and LFn3 would reduce excre-
tion of estrogens and metabolites in accordance with the
hypothesis that a low fat diet alters profiles of sex hor-
mones in a direction of reduced breast cancer risk. In-
creased excretion of urinary estrogens (defined as E1 +
E2 + E3 or E1 + E2) was associated with increased risk
of breast cancer in another study of postmenopausal
women [1]. Decreased excretion of estrogens was ob-
served in postmenopausal women from Asian nations
with relatively low breast cancer incidence and concomi-
tantly low intake of dietary fat [17-19].
In addition to total dietary fat, n-3 may play a role in
breast cancer prevention. Greenland Eskimos, with high
n-3 intake [20], have historically had a low incidence of
breast cancer [21,22]. However, this risk has increased as
Westernized and nontraditional foods have become more
prevalent in their diets [23]. Few studies have investigated
the relationship of n-3 and urinary sex hormone metabol-
ism in humans. Urinary 16αOH-E1 was reduced in the n-
3 fatty acid supplement arm in a pilot trial of high-risk
women [24]. In a study by Wu et al. [25] postmenopausal
vegetarian women consuming 2.14 g/day of n-3 doco-
sahexaenoic acid had no significant change in urinary
2:16αOH-E1 ratio following intervention. In our study,
2:16αOH-E1 ratio was not altered following 8 weeks of
dietary intervention.Conclusion
In conclusion, urinary sex hormone metabolism was
modestly altered in healthy postmenopausal women by
LF alone or with additional n-3.
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